02 Chikungunya Hills 508

Document text

Update on chikungunya vaccinesNational Center for Emerging and Zoonotic Infectious Diseases
Susan Hills MBBS MTH
CDC Lead , Chikungunya Vaccines Work Group
Arboviral Diseases Branch
Division of Vector -Borne Diseases
Fort Collins, Colorado
ACIP Meeting, June 26, 2024
•Manufactured by Bavarian Nordic
•Submission of BLA to FDA completed on June 17, 2024
•Licensure possible first half of 2025
•Intended age group is adolescents and adults aged ≥12 years
•Single dose schedule Virus -like particle chikungunya vaccine
•Manufactured by Valneva as IXCHIQ
•Licensed November 9, 2023
•Age group currently adults ≥18 years
•Single dose schedule Live attenuated chikungunya vaccine